187 related articles for article (PubMed ID: 2190316)
1. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.
Olivieri NF; Koren G; St Louis P; Freedman MH; McClelland RA; Templeton DM
Semin Hematol; 1990 Apr; 27(2):101-4. PubMed ID: 2190316
[No Abstract] [Full Text] [Related]
2. Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.
Olivieri NF; Templeton DM; Koren G; Chung D; Hermann C; Freedman MH; McClelland RA
Ann N Y Acad Sci; 1990; 612():369-77. PubMed ID: 2291564
[No Abstract] [Full Text] [Related]
3. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
[TBL] [Abstract][Full Text] [Related]
4. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
[TBL] [Abstract][Full Text] [Related]
5. Current status of iron chelation therapy with deferoxamine.
Cohen A
Semin Hematol; 1990 Apr; 27(2):86-90. PubMed ID: 2190321
[TBL] [Abstract][Full Text] [Related]
6. Oral iron chelators.
Nathan DG; Piomelli S
Semin Hematol; 1990 Apr; 27(2):83-5. PubMed ID: 2190320
[No Abstract] [Full Text] [Related]
7. Iron chelation.
Chandy M
J Assoc Physicians India; 1991 Sep; 39(9):665-6. PubMed ID: 1814896
[No Abstract] [Full Text] [Related]
8. Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
Kuo HT; Tsai MY; Peng CT; Wu KH
Hemoglobin; 2006; 30(2):291-9. PubMed ID: 16798654
[TBL] [Abstract][Full Text] [Related]
9. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
10. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
al-Refaie FN; Wonke B; Hoffbrand AV; Wickens DG; Nortey P; Kontoghiorghes GJ
Blood; 1992 Aug; 80(3):593-9. PubMed ID: 1638018
[TBL] [Abstract][Full Text] [Related]
12. Oral iron chelation with L1.
Agarwal MB; Viswanathan C; Ramanathan J; Massil DE; Shah S; Gupte SS; Vasandani D; Puniyani RR
Lancet; 1990 Mar; 335(8689):601. PubMed ID: 1968588
[No Abstract] [Full Text] [Related]
13. Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridines.
Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV
Prog Clin Biol Res; 1989; 309():107-14. PubMed ID: 2780745
[No Abstract] [Full Text] [Related]
14. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
Olivieri NF; Koren G; Hermann C; Bentur Y; Chung D; Klein J; St Louis P; Freedman MH; McClelland RA; Templeton DM
Lancet; 1990 Nov; 336(8726):1275-9. PubMed ID: 1978115
[TBL] [Abstract][Full Text] [Related]
15. Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).
Agarwal MB
Indian J Pediatr; 1993; 60(4):509-16. PubMed ID: 8262587
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
Agarwal MB; Gupte SS; Vasandani D; Viswanathan C; Puniyani RR; Ramanathan J; Massil DE; Shah S; Rajyadhyaksha GC; Bhave AA
J Assoc Physicians India; 1991 Sep; 39(9):669-72. PubMed ID: 1814897
[TBL] [Abstract][Full Text] [Related]
17. Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan.
Kuo HT; Peng CT; Tsai MY
Hemoglobin; 2006; 30(2):301-9. PubMed ID: 16798655
[TBL] [Abstract][Full Text] [Related]
18. Blood disorders: future trends in iron chelation.
Jordan D; Kontoghiorghes G
Nurs Stand; 1990 Oct 24-30; 5(5):25-7. PubMed ID: 2124864
[TBL] [Abstract][Full Text] [Related]
19. An orally active iron chelator.
Nathan DG
N Engl J Med; 1995 Apr; 332(14):953-4. PubMed ID: 7877655
[No Abstract] [Full Text] [Related]
20. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
